Cargando…
Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) is considered one of the most common genetic diseases and is characterised by the misfolding and polymerisation of the alpha-1 antitrypsin (AAT) protein within hepatocytes. The relevance of circulating polymers (CP) of AAT in the pathogenesis of lung...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442448/ https://www.ncbi.nlm.nih.gov/pubmed/34526035 http://dx.doi.org/10.1186/s12931-021-01842-5 |
_version_ | 1783753009972379648 |
---|---|
author | Núñez, Alexa Belmonte, Irene Miranda, Elena Barrecheguren, Miriam Farago, Georgina Loeb, Eduardo Pons, Mònica Rodríguez-Frías, Francisco Gabriel-Medina, Pablo Rodríguez, Esther Genescà, Joan Miravitlles, Marc Esquinas, Cristina |
author_facet | Núñez, Alexa Belmonte, Irene Miranda, Elena Barrecheguren, Miriam Farago, Georgina Loeb, Eduardo Pons, Mònica Rodríguez-Frías, Francisco Gabriel-Medina, Pablo Rodríguez, Esther Genescà, Joan Miravitlles, Marc Esquinas, Cristina |
author_sort | Núñez, Alexa |
collection | PubMed |
description | BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) is considered one of the most common genetic diseases and is characterised by the misfolding and polymerisation of the alpha-1 antitrypsin (AAT) protein within hepatocytes. The relevance of circulating polymers (CP) of AAT in the pathogenesis of lung and liver disease is not completely understood. Therefore, the main objective of our study was to determine whether there is an association between the levels of CP of AAT and the severity of lung and liver disease. METHOD: This was a cross-sectional study in patients with different phenotypes of AATD and controls. To quantify CP, a sandwich ELISA was performed using the 2C1 monoclonal antibody against AAT polymers. Sociodemographic data, clinical characteristics, and liver and lung parameters were collected. RESULTS: A cohort of 70 patients was recruited: 32 Pi*ZZ (11 on augmentation therapy); 29 Z-heterozygous; 9 with other genotypes. CP were compared with a control group of 47 individuals (35 Pi*MM and 12 Pi*MS). ZZ patients had the highest concentrations of CP (p < 0.001) followed by Z heterozygous. The control group and patients with Pi*SS and Pi*SI had the lowest CP concentrations. Pi*ZZ also had higher levels of liver stiffness measurements (LSM) than the remaining AATD patients. Among patients with one or two Z alleles, two patients with lung and liver impairment showed the highest concentrations of CP (47.5 µg/mL), followed by those with only liver abnormality (n = 6, CP = 34 µg/mL), only lung (n = 18, CP = 26.5 µg/mL) and no abnormalities (n = 23, CP = 14.3 µg/mL). Differences were highly significant (p = 0.004). CONCLUSIONS: Non-augmented Pi*ZZ and Z-patients with impaired lung function and increased liver stiffness presented higher levels of CP than other clinical phenotypes. Therefore, CP may help to identify patients more at risk of developing lung and liver disease and may provide some insight into the mechanisms of disease. |
format | Online Article Text |
id | pubmed-8442448 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84424482021-09-15 Association between circulating alpha-1 antitrypsin polymers and lung and liver disease Núñez, Alexa Belmonte, Irene Miranda, Elena Barrecheguren, Miriam Farago, Georgina Loeb, Eduardo Pons, Mònica Rodríguez-Frías, Francisco Gabriel-Medina, Pablo Rodríguez, Esther Genescà, Joan Miravitlles, Marc Esquinas, Cristina Respir Res Research BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) is considered one of the most common genetic diseases and is characterised by the misfolding and polymerisation of the alpha-1 antitrypsin (AAT) protein within hepatocytes. The relevance of circulating polymers (CP) of AAT in the pathogenesis of lung and liver disease is not completely understood. Therefore, the main objective of our study was to determine whether there is an association between the levels of CP of AAT and the severity of lung and liver disease. METHOD: This was a cross-sectional study in patients with different phenotypes of AATD and controls. To quantify CP, a sandwich ELISA was performed using the 2C1 monoclonal antibody against AAT polymers. Sociodemographic data, clinical characteristics, and liver and lung parameters were collected. RESULTS: A cohort of 70 patients was recruited: 32 Pi*ZZ (11 on augmentation therapy); 29 Z-heterozygous; 9 with other genotypes. CP were compared with a control group of 47 individuals (35 Pi*MM and 12 Pi*MS). ZZ patients had the highest concentrations of CP (p < 0.001) followed by Z heterozygous. The control group and patients with Pi*SS and Pi*SI had the lowest CP concentrations. Pi*ZZ also had higher levels of liver stiffness measurements (LSM) than the remaining AATD patients. Among patients with one or two Z alleles, two patients with lung and liver impairment showed the highest concentrations of CP (47.5 µg/mL), followed by those with only liver abnormality (n = 6, CP = 34 µg/mL), only lung (n = 18, CP = 26.5 µg/mL) and no abnormalities (n = 23, CP = 14.3 µg/mL). Differences were highly significant (p = 0.004). CONCLUSIONS: Non-augmented Pi*ZZ and Z-patients with impaired lung function and increased liver stiffness presented higher levels of CP than other clinical phenotypes. Therefore, CP may help to identify patients more at risk of developing lung and liver disease and may provide some insight into the mechanisms of disease. BioMed Central 2021-09-15 2021 /pmc/articles/PMC8442448/ /pubmed/34526035 http://dx.doi.org/10.1186/s12931-021-01842-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Núñez, Alexa Belmonte, Irene Miranda, Elena Barrecheguren, Miriam Farago, Georgina Loeb, Eduardo Pons, Mònica Rodríguez-Frías, Francisco Gabriel-Medina, Pablo Rodríguez, Esther Genescà, Joan Miravitlles, Marc Esquinas, Cristina Association between circulating alpha-1 antitrypsin polymers and lung and liver disease |
title | Association between circulating alpha-1 antitrypsin polymers and lung and liver disease |
title_full | Association between circulating alpha-1 antitrypsin polymers and lung and liver disease |
title_fullStr | Association between circulating alpha-1 antitrypsin polymers and lung and liver disease |
title_full_unstemmed | Association between circulating alpha-1 antitrypsin polymers and lung and liver disease |
title_short | Association between circulating alpha-1 antitrypsin polymers and lung and liver disease |
title_sort | association between circulating alpha-1 antitrypsin polymers and lung and liver disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442448/ https://www.ncbi.nlm.nih.gov/pubmed/34526035 http://dx.doi.org/10.1186/s12931-021-01842-5 |
work_keys_str_mv | AT nunezalexa associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease AT belmonteirene associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease AT mirandaelena associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease AT barrechegurenmiriam associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease AT faragogeorgina associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease AT loebeduardo associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease AT ponsmonica associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease AT rodriguezfriasfrancisco associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease AT gabrielmedinapablo associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease AT rodriguezesther associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease AT genescajoan associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease AT miravitllesmarc associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease AT esquinascristina associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease |